- Home
- ADV vs ZVRA Comparison
ADV vs ZVRA Comparison
Compare ADV & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- ZVRA
- Stock Information
- Founded
- ADV 1987
- ZVRA 2006
- Country
- ADV United States
- ZVRA United States
- Employees
- ADV N/A
- ZVRA N/A
- Industry
- ADV Business Services
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- ZVRA Health Care
- Exchange
- ADV Nasdaq
- ZVRA Nasdaq
- Market Cap
- ADV 415.1M
- ZVRA 400.8M
- IPO Year
- ADV N/A
- ZVRA 2015
- Fundamental
- Price
- ADV $1.15
- ZVRA $8.66
- Analyst Decision
- ADV Strong Buy
- ZVRA Strong Buy
- Analyst Count
- ADV 1
- ZVRA 8
- Target Price
- ADV $2.50
- ZVRA $22.29
- AVG Volume (30 Days)
- ADV 633.6K
- ZVRA 608.4K
- Earning Date
- ADV 05-12-2025
- ZVRA 05-13-2025
- Dividend Yield
- ADV N/A
- ZVRA N/A
- EPS Growth
- ADV N/A
- ZVRA N/A
- EPS
- ADV N/A
- ZVRA N/A
- Revenue
- ADV $3,526,704,000.00
- ZVRA $40,588,000.00
- Revenue This Year
- ADV N/A
- ZVRA $276.77
- Revenue Next Year
- ADV N/A
- ZVRA $86.15
- P/E Ratio
- ADV N/A
- ZVRA N/A
- Revenue Growth
- ADV N/A
- ZVRA 46.47
- 52 Week Low
- ADV $1.04
- ZVRA $4.20
- 52 Week High
- ADV $4.16
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- ADV 42.45
- ZVRA 61.06
- Support Level
- ADV $1.11
- ZVRA $8.21
- Resistance Level
- ADV $1.32
- ZVRA $8.78
- Average True Range (ATR)
- ADV 0.11
- ZVRA 0.37
- MACD
- ADV 0.01
- ZVRA -0.00
- Stochastic Oscillator
- ADV 33.33
- ZVRA 80.16
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.